Cargando…
Microbiome in Chronic Kidney Disease
The gut microbiome is a complex collection of microorganisms with discrete characteristics and activities. Its important role is not restricted to food digestion and metabolism, but extends to the evolution, activation and function of the immune system. Several factors, such as mode of birth, diet,...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604691/ https://www.ncbi.nlm.nih.gov/pubmed/36294946 http://dx.doi.org/10.3390/life12101513 |
_version_ | 1784817878094053376 |
---|---|
author | Tourountzis, Theodoros Lioulios, Georgios Fylaktou, Asimina Moysidou, Eleni Papagianni, Aikaterini Stangou, Maria |
author_facet | Tourountzis, Theodoros Lioulios, Georgios Fylaktou, Asimina Moysidou, Eleni Papagianni, Aikaterini Stangou, Maria |
author_sort | Tourountzis, Theodoros |
collection | PubMed |
description | The gut microbiome is a complex collection of microorganisms with discrete characteristics and activities. Its important role is not restricted to food digestion and metabolism, but extends to the evolution, activation and function of the immune system. Several factors, such as mode of birth, diet, medication, ageing and chronic inflammation, can modify the intestinal microbiota. Chronic kidney disease (CKD) seems to have a direct and unique effect, as increased urea levels result in alteration of the gut microbiome, leading to overproduction of its metabolites. Therefore, potentially noxious microbial uremic toxins, which have predominantly renal clearance, including p-cresyl sulfate, indoxyl sulfate and N-oxide of trimethylamine [Trimethylamine-N-Oxide (TMAO)], accumulate in human’s body, and are responsible not only for the clinical implications of CKD, but also for the progression of renal failure itself. Certain changes in gut microbiome are observed in patients with end stage renal disease (ESRD), either when undergoing hemodialysis or after kidney transplantation. The purpose of this review is to summarize the changes of gut microbiome and the protein bound uremic toxins which are observed in CKD and in different kidney replacement strategies. In addition, we attempt to review the connection between microbiome, clinical implications and immune response in CKD. |
format | Online Article Text |
id | pubmed-9604691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96046912022-10-27 Microbiome in Chronic Kidney Disease Tourountzis, Theodoros Lioulios, Georgios Fylaktou, Asimina Moysidou, Eleni Papagianni, Aikaterini Stangou, Maria Life (Basel) Review The gut microbiome is a complex collection of microorganisms with discrete characteristics and activities. Its important role is not restricted to food digestion and metabolism, but extends to the evolution, activation and function of the immune system. Several factors, such as mode of birth, diet, medication, ageing and chronic inflammation, can modify the intestinal microbiota. Chronic kidney disease (CKD) seems to have a direct and unique effect, as increased urea levels result in alteration of the gut microbiome, leading to overproduction of its metabolites. Therefore, potentially noxious microbial uremic toxins, which have predominantly renal clearance, including p-cresyl sulfate, indoxyl sulfate and N-oxide of trimethylamine [Trimethylamine-N-Oxide (TMAO)], accumulate in human’s body, and are responsible not only for the clinical implications of CKD, but also for the progression of renal failure itself. Certain changes in gut microbiome are observed in patients with end stage renal disease (ESRD), either when undergoing hemodialysis or after kidney transplantation. The purpose of this review is to summarize the changes of gut microbiome and the protein bound uremic toxins which are observed in CKD and in different kidney replacement strategies. In addition, we attempt to review the connection between microbiome, clinical implications and immune response in CKD. MDPI 2022-09-28 /pmc/articles/PMC9604691/ /pubmed/36294946 http://dx.doi.org/10.3390/life12101513 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Tourountzis, Theodoros Lioulios, Georgios Fylaktou, Asimina Moysidou, Eleni Papagianni, Aikaterini Stangou, Maria Microbiome in Chronic Kidney Disease |
title | Microbiome in Chronic Kidney Disease |
title_full | Microbiome in Chronic Kidney Disease |
title_fullStr | Microbiome in Chronic Kidney Disease |
title_full_unstemmed | Microbiome in Chronic Kidney Disease |
title_short | Microbiome in Chronic Kidney Disease |
title_sort | microbiome in chronic kidney disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604691/ https://www.ncbi.nlm.nih.gov/pubmed/36294946 http://dx.doi.org/10.3390/life12101513 |
work_keys_str_mv | AT tourountzistheodoros microbiomeinchronickidneydisease AT liouliosgeorgios microbiomeinchronickidneydisease AT fylaktouasimina microbiomeinchronickidneydisease AT moysidoueleni microbiomeinchronickidneydisease AT papagianniaikaterini microbiomeinchronickidneydisease AT stangoumaria microbiomeinchronickidneydisease |